David joined Pivotal bioVentures in 2018 and serves as a Venture Partner, responsible for leading new investments at the fund. During his time with Pivotal he has been leading several investments in innovative healthcare companies as well as company incubations in this field. He is a member of the Board of Directors of several healthcare companies.
Prior to Pivotal, David served as the Chief Business Officer at BioLineRx (NASDAQ: BLRX), where he was responsible for licensing, M&A, strategic alliances and investor relations, and built partnerships between BioLineRx and several leading life sciences companies. He was also responsible for investor relations and was involved in several successful financing rounds on NASDAQ. Prior to his role at BioLineRx David was working for Sanofi, one of the leading global pharmaceutical companies. He held a number of management roles in corporate development, including running M&A projects and licensing transactions.
David gained his MBA at the Tuck School of Business at Dartmouth and his B.A. in statistics and political science at the University of Haifa.